No Data
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
No Data
No Data
